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To explore the extent of thrombocytopenia (TCP), anaemia, and leukopenia in patients with 
hepatitis C and evaluate how they impact the management of antiviral therapy (AVT), the 
attainment of sustained virological response (SVR), and some therapy-related adverse events. 
Materials and Methods 
The Scottish Hepatitis C Clinical Database was used in this retrospective study. The 
prevalence of TCP, anaemia, and leukopenia were evaluated. The impact of the three 
deficiencies on AVT management, serious adverse events, and SVR attainment were assessed 
in patients received therapy. 
Results 
The prevalence of TCP, anaemia, and leukopenia were 18.5%, 0.9%, and 0.2% among 4,907 
treated patients at baseline, increasing to 72%, 25.8%, and 5.4% during treatment, 
respectively. Dose reduction occurred in 29.3% of the patients without TCP, this percentage 
was higher in those with baseline TCP (53%) and in those acquired during treatment (35%). 
Similar results were found for anaemia and leukopenia. Baseline TCP (OR=0.67, p<0.001) 
and baseline anaemia (OR=0.43, p=0.03) were identified as risk factors associated with lower 
SVR rate, acquired TCP and anaemia were not associated with reduced SVR. 
Conclusions 
Baseline TCP or anaemia increased risk of dose cessation. Patients acquired TCP, anaemia, 
or leukopenia during treatment did not exhibit compromised SVR rates, whereas, patients 
with TCP or anaemia at baseline did. The potential benefit of growth factors in maintaining 
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SVR rate is likely to be confined those with baseline TCP or anaemia rather than those who 
acquire it during therapy, where dose reduction does not appear to reduce the chance of SVR. 
Keywords: chronic hepatitis, hepatitis C virus, thrombocytopenia, anaemia, leukopenia, 





Thrombocytopenia (TCP), anaemia, and leukopenia can be complications of chronic liver 
disease and considered indicators of advanced disease. The causes of them are multi-factorial 
including portal hypertension, hypersplenism, decreased thrombopoietin production, and 
virus induced bone marrow suppression [1-3]. Furthermore, TCP, anaemia, and leukopenia 
can also be significant side effects during hepatitis C therapy which involves peginterferon 
alpha and ribavirin, which was the standard of care for hepatitis C until very recently [4, 5] 
and with the current high cost of new direct acting antivirals may remain the mainstay of 
therapy for many patients for the foreseeable future. For patients with hepatitis C virus (HCV) 
genotype 1, the addition of protease inhibitors, boceprevir and telaprevir, has been proved to 
improve efficacy of antiviral therapy (AVT), but further increases the frequency as well as 
the severity of anaemia [6, 7]. As a result, in some patients with HCV infection, TCP, 
anaemia, and leukopenia prevent initiation of AVT, while in others even if they are able to 
initiate therapy they have to undergo dose reductions and or early treatment discontinuation 
(i.e. dose cessation) to manage these three deficiencies. Such sub-optimal therapy has been 
demonstrated to be associated with a reduced ability to achieve Sustained Virological 
Response (SVR) [1, 5, 6, 8-10]. The development and approval for use of second generation 
direct acting antivirals means that some patients have the option of interferon free regimens 
which avoid the cytopenias associated with interferon alpha, but the cost of these regimens 
means that many patients, in many countries, will continue to be treated with interferon based 
regimens. 
Limited data exists about the extent of TCP, anaemia, and leukopenia amongst 
patients with HCV, both before treatment and in response to therapy. Especially for TCP, 
where if there is data it usually refers to normal range definitions of TCP i.e. platelet count < 
150 × 109/L, which while a limit of normality, is meaningless in terms of clinical risk of 
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bleeding or indication for therapy reduction or cessation. However in clinical practice, TCP 
generally impacts management of patients with HCV at lower platelet levels and there is lack 
of data regarding the prevalence of TCP at these clinically meaningful values. In addition, 
current management of TCP, anaemia, and leukopenia in patients who are being treated for 
HCV is dose reduction of the AVT or even treatment cessation. There is the option to use 
growth factors to support platelets, leukocytes and erythrocytes but their current role is not 
well defined. However, there is limited small scale data to show how many patients are 
impacted by this and how such sub-optimal AVT impacts treatment success i.e. attainment of 
SVR.  
 The objectives of this study were to understand the extent of TCP, anaemia, and 
leukopenia (prevalence) among the patients with HCV in a whole country treatment 
population (Scotland), to evaluate how TCP, anaemia, and leukopenia impact the 
management of AVT, as well as to assess the SVR rates and some other therapy related 
adverse events (on-treatment bleeding, hepatic decompensation, sepsis and thromboembolic 
events) among the patients received AVT for HCV, doing this for the first time at a national 
level avoiding the selection biases associated with specialist centres treating more advanced 
disease. 
 
Materials and methods 
This retrospective descriptive database study is based on the National HCV Clinical database 
held at Health Protection Scotland (HPS) who collected data since year 2002 from patients 
diagnosed with active hepatitis C in 11 Scottish National Health Service (NHS) board areas 
running HCV treatment clinics [11]. Patients were defined as a unique combination of 
forename initial, surname soundex, date of birth, and gender. All patients in the database who 
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had a record of a positive PCR test for HCV were initially included. Among the included 
patients, the haematology test records with missing platelet count, haemoglobin level or white 
cell count were excluded. 
The patients who received AVT were selected to further explore how TCP, anaemia, 
and leukopenia impacted the management of AVT (i.e. treatment dosing), SVR attainment, 
and the onset of serious adverse events. As part of routine clinical practice, blood counts are 
monitored before treatment, during, end of treatment (that would identify dose reductions and 
dose cessations), and at 6 months post treatment (that would identify SVR). For the patients 
who were treated twice or more, only the latest treatment was considered. The platelet count, 
haemoglobin level and white cell count prior to the initiation of AVT were considered as 
baseline values. The lowest platelet count, haemoglobin level, and white cell count during 
treatment were considered as nadir values during AVT. 
 Continuous variables were summarised as median with interquartile range and 
categorical variables as frequencies with percentages. The prevalence at baseline of TCP, 
anaemia, and leukopenia were determined both in the patients without AVT and in those who 
received AVT. Baseline refers to the first attendance - with TCP, anaemia and leukopenia 
defined as according to mean laboratory test results within a 3 month window around this 
first attendance date. Given that in clinical practice TCP generally impacts management at 
lower platelet levels than the textbook clinical definition i.e. platelet count < 150 × 109/L, the 
prevalence of TCP was evaluated in the following ranges of platelet count: (1) 100 - 150 × 
109/L; (2) 75 - 100 × 109/L; (3) 50 - 75 × 109/L; (4) 25 - 50 × 109/L; (5) ≤ 25 × 109/L. 
Anaemia and leukopenia were defined as a single occurrence of haemoglobin level < 10g/dl 
and white cell count < 1.5 × 109/L, respectively. 
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 Among the patients who received treatment, dose reductions and dose cessations were 
identified according to different severity of TCP, anaemia, and leukopenia. The impact of 
TCP, anaemia, and leukopenia on serious adverse events during AVT were assessed. SVR 
rates were also evaluated according to different status of TCP, anaemia, and leukopenia (i.e. 
never acquired, acquired at baseline, and acquired during AVT), and according to different 
management of AVT (i.e. optimal dosing, dose reduction alone, dose cessation alone, and 
both dose reduction and dose cessation).   
 Logistic regression was used to investigate the impact of baseline characteristics on 
SVR attainment after the last registered treatment. The age at initiation of AVT was 
considered as a continuous variable, and the baseline albumin level, neutrophil count, alanine 
aminotransferase (ALT) level, bilirubin level, haemoglobin level, and white cell count were 
all grouped as normal or abnormal according to their respective threshold values. Platelet 
count at baseline was also grouped as normal and abnormal, using the cut-off value of the 
clinical definition, i.e. 150 × 109/L. Variables with a p value ≤ 0.2 in the univariate logistic 
regression were included in the multivariate analysis [12]. A multiple imputation procedure 
was conducted to impute missing baseline data for the multivariate logistic regression. Every 
model during the model building procedure was fitted to 10 imputed datasets arising from the 
multiple imputation procedure. The model selection procedure was then carried out using a 
backward stepwise regression based on the Akaike information criterion (AIC) statistic. The 
model with the smallest AIC was considered the optimal model. The Hosmer-Lemeshow 
goodness of fit test [12] for logistic regression was carried out to see how well the final 







Overall, there were 18,603 HCV antibody positive patients in the database. The 4,743 
patients who had no record of a positive HCV PCR test were excluded. This group are a 
combination of those who did not attend follow up or had spontaneous resolution of their 
HCV infection. Another 3,034 patients were also excluded because of missing records of 
platelet count, haemoglobin level, or white cell count. In the final cohort, there were 10,826 
patients with chronic HCV infection, of whom 7,700 (71%) were male, 10,135 (94%) were 
white ethnicity, 4,343 (40%) were with HCV genotype 1, 4,642 (43%) were with HCV 
genotype 3, 193 (2%) had HIV co-infection, and 630 (6%) had previous AVT experience. In 
terms of disease stage, 1,629 (15%) had established cirrhosis at baseline. The patients 
received AVT were older than those without AVT. The duration of AVT was 24 or 48 
weeks for the patients who were treatment naïve, and it was not extended for those who 
had previous AVT experience. The patients with HCV genotype 1 were not likely to 
proceed to antiviral therapy, while those with HCV genotype 3 were more likely to 
response to interferon. Among the 193 patients with combined infection of HCV and 
HIV, 86 received HCV antiviral therapy, where most of them (75 of 86) were treated by 
peginterferon and ribavirin, 7 received combined treatment of peginterferon, ribavirin 
and telaprevir, 3 received peginterferon alone, and only 1 received combined treatment 
of interferon and ribavirin. The other characteristics among these two groups were similar 





The prevalence of TCP (in different ranges), anaemia, and leukopenia are shown in Table 2. 
There were more patients whose platelet count were below 75 × 109/L in the “No-AVT” 
group than that at baseline in the AVT group, which could be one reason that prevented 
initiation of AVT for some patients. The prevalence of anaemia in the “No-AVT” group (5%, 
95% CI: 4.4% - 5.5%) was also much higher than that at baseline in the AVT group (0.9%, 
95% CI: 0.7% - 1.2%). Among the 4,907 treated patients, the prevalence of TCP, anaemia, 
and leukopenia at any point during AVT were much higher at 72% (95% CI: 70.7% - 73.3%), 
25.8% (95% CI: 24.6% - 27%), and 5.4% (95% CI: 4.7% - 6%), respectively.  
 
Impact of TCP, anaemia, and leukopenia on AVT dosing 
The numbers and percentages of patients who received optimal dosing, who underwent dose 
reduction or dose cessation, according to different status of TCP, anaemia, and leukopenia are 
shown in Table 3. Overall, among the 4,907 treated patients, 2,338 patients (47.6%) received 
optimal dosing, 1,802 patients (36.7%) underwent dose reduction, and 1,367 patients (27.9%) 
underwent dose cessation. There was evidence that 600 patients underwent both dose 
reduction and cessation. The detailed percentages are shown in the last column of Table 
3. The patients with TCP (at baseline or acquired during AVT) had higher risk of undergoing 
dose reduction than those never had TCP (53% at baseline, 35% during AVT, 29.3% for non-
TCP). Similar results can be found for anaemia and leukopenia. However, only baseline TCP 
and baseline anaemia increased the risk of undergoing dose cessation.  
Table 4 shows the detailed number of patients who underwent dose reduction and or 
dose cessation. Among all the 1,802 dose reductions, 162 (9%) were associated with TCP, 
289 (16%) were associated with anaemia, and only 13 (0.7%) were associated with 
leukopenia. Among the 1,367 dose cessations, 42 (3.1%) were associated with TCP, 29 (2.1%) 
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were associated with anaemia, and only 8 (0.6%) were associated with leukopenia. Some 
reductions or cessations were associated with more than one of the three deficiencies, since 
the patients could have all three. The patients who had an abnormal platelet count at baseline 
were more likely to undergo TCP-related dose reduction and or TCP-related dose cessation 
than those who had a normal baseline platelet count (reduction: 24.6% vs 3.3%; cessation: 
10.8% vs 0.5%). The proportion of patients undergoing anaemia-related dose reduction 
among the patients who had abnormal haemoglobin level at baseline was around two times 
higher than that among those with normal haemoglobin level at baseline (30.8% vs 15.8%). 
All leukopenia-related reductions and cessations occurred among the patients with a normal 
white cell count at baseline (reduction: 0.7%; cessation: 0.6%). However, the number of 
patients with an abnormal haemoglobin level (only 46 patients) or an abnormal white cell 
count (only 11 patients) at baseline was quite small. 
  
Impact of TCP, anaemia, and leukopenia on serious adverse events on therapy 
The number of patients who had some serious adverse events recorded in the database (on-
treatment bleeding, sepsis, hepatic decompensation, and thromboembolic events) on therapy 
are shown in Table 5. Overall the rates were low and not strongly associated with TCP, 
anaemia, or leukopenia, but this may have been confounded by dose alteration. Among the 
4,907 treated patients, 110 patients (2.2%) had on-treatment bleeding, 3 (< 0.1%) had sepsis, 
5 (< 0.1%) had hepatic decompensation, and 2 (< 0.1%) had thromboembolic events. The 
patients with both TCP and leukopenia had the highest risk of on-treatment bleeding (5.43%). 
The other three adverse events all occurred in patients with either TCP alone or with both 




Impact of TCP, anaemia, and leukopenia on SVR attainment 
The SVR rates of the patients attained, according to different status of TCP, anaemia, and 
leukopenia, are shown in Table 6. The patients who never had TCP and the patient who 
acquired TCP during AVT had similar overall SVR rates (55.8% and 55.5%), while those 
who had baseline TCP had a much lower SVR rate of 36.5% (95% CI: 33.4% - 39.7%). In the 
“Non-TCP” group and the “Acquired TCP during AVT” group, the patients whose dose level 
were reduced had similar SVR rate as those who received optimal dosing (70.3% vs 68.7%; 
66.7% vs 61.4%). Similar results were found for anaemia and leukopenia. However, there 
were no patients who had baseline leukopenia and underwent dose cessation alone, therefore 
the SVR rate in this group was not reported. Moreover, there were only 2 patients who had 
baseline leukopenia and received both dose reduction and dose cessation, and 1 of them 
achieved SVR, which lead to a higher SVR rate of 50% (95% CI: 1.3% - 98.7%) in this group 
than those who never had leukopenia and those who acquired leukopenia during AVT. 
Clearly the small number makes it impossible to draw any conclusion.  
 
Overall Risk factors for SVR attainment 
In the univariate analysis (Table 7), baseline TCP (OR = 0.46, 95% CI: 0.4 - 0.53, p < 0.001) 
and baseline anaemia (OR = 0.25, 95% CI: 0.13 - 0.51, p < 0.001) were inversely associated 
with SVR, whereas baseline leukopenia did not significantly reduce the SVR rate (OR = 0.34, 
95% CI: 0.09 - 1.3, p < 0.115). In the multivariate analysis, baseline TCP (OR: 0.67, 95% CI: 
0.56 - 0.81, p < 0.001) and baseline anaemia (OR: 0.43, 95% CI: 0.2 - 0.92, p = 0.03) were 
identified as risk factors associated with lower SVR rate. The variables with p values greater 
than 0.05 (gender and baseline neutrophil) were kept in the final model since they could 
provide some useful information as well as make the model achieve the smallest value of 
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AIC. A 10-fold Hosmer-Lemeshow goodness of fit test for the final multivariate logistic 
regression model gave a p value 0.148, which indicated the model fitted the data well. 
 
Discussion 
This study determined the prevalence of TCP, anaemia, and leukopenia, both prior to and 
during treatment of HCV, among all the known patients with HCV in a whole country, 
Scotland. The rate of mild baseline TCP was much higher than the reported rate of cirrhosis, 
while there may have been under ascertainment of cirrhosis due to the removal of a 
requirement for liver biopsy to qualify for treatment in the later stages of the cohort and 
limited availability of non-invasive assessment of liver fibrosis, it is unlikely that the rate was 
as high as the rate of TCP. It is more likely that alcohol and other life style factors may have 
been having an effect. The much higher prevalence of TCP, anaemia, and leukopenia during 
AVT confirmed unsurprisingly that the three deficiencies were all side effects triggered by 
interferon based therapy hepatitis C. 
 Among the patients who received treatment for HCV, the impact of TCP, anaemia, 
and leukopenia on the management of AVT and on the SVR attainment were also evaluated. 
TCP, anaemia, and leukopenia all increased the risk of undergoing dose reduction. Only 
baseline TCP and baseline anaemia increased the risk of undergoing dose cessation. 
Acquirement of TCP, anaemia, and leukopenia during AVT did not have significant influence 
on SVR attainment, while the presence of TCP and or anaemia at baseline significantly 
reduced the chance to achieve SVR. This can be explained by the higher risk of undergoing 
dose cessation in the patients with baseline TCP or baseline anaemia, which can directly 
reduce the likelihood of SVR but also important is that these parameters are surrogate 
markers of cirrhosis, which is a well-known factor for reduced chance of SVR. The reasons 
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of undergoing dose reduction were complicated. The majority of the reductions were 
triggered by patient-related clinical side effects during treatment, while some reductions were 
due to blood-test-triggered reductions such as TCP, anaemia, or leukopenia, which can be 
regarded as drug toxicity. The patients who demonstrated some toxicity might have been 
exposure up to and beyond their optimum dose and dose reduction brought them to optimum 
dose, but those without toxicity might not have been exposure to their optimum dose, this 
may in particular be true of ribavirin and to a less extent interferon. This may be the reason 
that patients who underwent dose reduction had similar or even slightly higher SVR rate than 
those who received apparently optimal dosing without dose reduction. In this cohort, there 
was no documented cases of growth factors being used. The structure of the database 
means these may not have been well recorded. However, very few patients, if any, 
received any growth factor support such as erythropoietin, granulocyte colony 
stimulating factor or eltrombopag. So the vast majority of patient events in this cohort 
related to TCP, anaemia, or leukopenia were managed by dose reduction. It is very clear from 
our data that those patients who had no TCP, anaemia, or leukopenia at baseline but acquired 
it during therapy were managed with dose reduction and had no reduction in their rate of 
SVR. This suggests that growth factor support is unnecessary for most patients with acquired 
TCP, anaemia, or leukopenia, and the role of these agents lies in improving baseline 
abnormalities in the hope that this might improve SVR attainment. The assessment of the 
role of growth factors according to timing of its use is out of the scope of this study. The 
co-existence of anaemia seems to increase the risk of sepsis, hepatic decompensation and 
thromboembolic events among TCP patients. 
 In summary we have shown in a very large cohort of unselected patients 
representative of a whole nation the rates of thrombocytopenia, anaemia, and leukopenia in 
HCV infection patients and demonstrated what happens to these during interferon based 
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therapy. Patients having pre-treatment thrombocytopenia, anaemia, or leukopenia had 
increased the risk of undergoing dose cessation and a reduced chance of SVR. However, 
acquiring thrombocytopenia, anaemia, and leukopenia during treatment did not have 
significant impact on attaining SVR, when managed with dose reduction compared to those 
who did not need dose reduction. This was achieved in a cohort with very little use of growth 
factor support before or during treatment. The potential benefit of growth factors in 
maintaining SVR rate is likely to be confined to those with baseline thrombocytopenia or 
anaemia rather than those who acquired it during therapy, unless they do not respond to dose 
reduction. Overall, patients who acquire thrombocytopenia, anaemia, and leukopenia during 
therapy can be managed first line with dose reduction. If this is successfully and avoids dose 
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Table 1. Patient demographics summary. 
Characteristics 
Total  
(n = 10,826) 
No AVT  
(n = 5,919) 
AVT  
(n = 4,907) 
Age1 (range) 45 (38 – 52) 44 (37 – 50) 47 (39 – 54) 
Gender 
      Male 
      Female 














      White 
      Non-white 














      1 
      3 
      Others 

















      Positive 
      Negative 













Cirrhosis at entry 1,629 (15%) 1,013 (17%) 616 (13%) 
Previous AVT experienced 630 (6%) -- 630 (16%) 




Table 2. Prevalence of TCP, anaemia, and leukopenia for patients without AVT and patients received 
AVT (at baseline and during AVT). 
Characteristic Range 
Prevalence1 (95% CI) 
No AVT  
(n = 5,919) 
AVT (n = 4,907) 
Baseline During AVT 
Platelet count 100 – 150 (×109/L) 12.7 (11.8 – 13.5) 12.3 (11.4 – 13.2) 33.5 (32.2 – 34.9) 
 75 – 100 (×109/L) 3.8 (3.3 – 4.2) 3.1 (2.6 – 3.6) 16.4 (15.3 – 17.4) 
 50 – 75 (×109/L) 3.4 (2.9 – 3.8) 2 (1.6 – 2.4) 10.7 (9.9 – 11.6) 
 25 – 50 (×109/L) 2.6 (2.2 – 3.0) 0.7 (0.5 – 0.9) 8 (7.2 – 8.7) 
 ≤ 25 (×109/L) 0.9 (0.6 – 1.1) 0.3 (0.1 – 0.4) 3.4 (2.9 – 3.9) 
 Total (<150×109/L) 23.2 (22.2 – 24.3) 18.5 (17.4 – 19.5) 72 (70.7 – 73.3) 
Haemoglobin level < 10 g/dl 5 (4.4 – 5.5) 0.9 (0.7 – 1.2) 25.8 (24.6 – 27) 
White cell count < 1.5 × 109/L 0.3 (0.2 – 0.5) 0.2 (0.1 – 0.4) 5.4 (4.7 – 6) 





Table 3. Number of patients received optimal dosing, underwent dose reduction or dose cessation, 













TCP      
Non-TCP 1,352 689 (51%) 396 (29.3%) 400 (29.6%) 133 (9.8%) 
present at baseline 906 277 (30.6%) 480 (53%) 342 (37.7%) 193 (21.3%) 
Acquired during AVT 2,649 1,372 (51.8%) 926 (35%) 625 (23.6%) 274 (10.3%) 
Anaemia      
Non-anaemia 3,627 1,892 (52.2%) 1,096 (30.2%) 1,027 (28.3%) 388 (10.7%) 
present at baseline 46 14 (30.4%) 26 (56.5%) 14 (30.4%) 8 (17.4%) 
Acquired during AVT 1,234 432 (35%) 680 (55.1%) 326 (26.4%) 204 (16.5%) 
Leukopenia      
Non-leukopenia 4,640 2,244 (48.4%) 1,649 (35.5%) 1,296 (27.9%) 549 (11.8%) 
present at baseline 11 3 (27.3%) 8 (72.7%) 2 (18.2%) 2 (18.2%) 
Acquired during AVT 256 91 (35.5%) 145 (56.6%) 69 (27%) 49 (19.1%) 












Table 4. Dose reductions and dose cessations associated with TCP, anaemia, and leukopenia, according to 
different platelet count, haemoglobin level, and white cell count. 









Dose reductions Dose cessations 
Total TCP-related Total TCP-related 
Normal 
(≥ 150) 
≥ 150 1,352 396 1 (0.3%) 400 0 (0%) 
100 – 150 1,502 486 4 (0.8%) 358 0 (0%) 
75 – 100 635 221 4 (1.8%) 136 0 (0%) 
50 – 75 307 119 13 (10.9%) 69 1 (1.4%) 
25 – 50 125 65 17 (26.2%) 37 1 (2.7%) 
< 25 80 38 5 (13.2%) 25 3 (12.0%) 
Total 4,001 1,322 44 (3.3%) 1,025 5 (0.5%) 
Abnormal 
(< 150) 
≥ 150 22 8 0 (0%) 8 0 (0%) 
100 – 150 144 64 1 (1.6%) 48 0 (0%) 
75 – 100 169 81 6 (7.4%) 55 3 (5.5%) 
50 – 75 220 100 20 (20.0%) 74 7 (9.5%) 
25 – 50 266 176 66 (37.5%) 113 14 (12.4%) 
< 25 85 51 25 (49.0%) 44 13 (29.5%) 
Total 906 480 118 (24.6%) 342 37 (10.8%) 
Total 4,907 1,802 162 (9%) 1,367 42 (3.1%) 

















≥ 10 3,627 1,096 55 (5%) 1,027 5 (0.5%) 
8 – 10 1,023 568 193 (34%) 240 12 (5%) 
< 8 211 112 33 (29.5%) 86 12 (14%) 
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Total 4,861 1,776 281 (15.8%) 1,353 29 (2.1%) 
Abnormal 
(< 10) 
≥ 10 14 8 0 (0%) 8 0 (0%) 
8 – 10 27 15 6 (40%) 6 0 (0%) 
< 8 5 3 2 (66.7%) 0 0 (0%) 
Total 46 26 8 (30.8%) 14 0 (0%) 
Total 4,907 1,802 289 (16%) 1,367 29 (2.1%) 

















≥ 1.5 4,640 1,649 7 (0.4%) 1,296 6 (0.5%) 
< 1.5 256 145 6 (4.1%) 69 2 (2.9%) 
Total 4,896 1,794 13 (0.7%) 1,365 8 (0.6%) 
Abnormal 
(< 1.5) 
≥ 1.5 3 1 0 (0%) 0 0 (-) 
< 1.5 8 7 0 (0%) 2 0 (0%) 
Total 11 8 0 (0%) 2 0 (0%) 
Total 4,907 1,802 13 (0.7%) 1,367 8 (0.6%) 






Table 5. Profile of adverse events on treatment, according to different combinations of any occurrence of 









None 1,094 19 (1.74%) 0 0 0 
TCP only 2,430 53 (2.18%) 2 (0.08%) 2 (0.08%) 1 (0.04%) 
Anaemia only 235 6 (2.55%) 0 0 0 
Leukopenia only 11 0 0 0 0 
TCP & Anaemia 881 23 (2.61%) 1 (0.11%) 3 (0.34%) 1 (0.11%) 
TCP & Leukopenia 92 5 (5.43%) 0 0 0 
Anaemia & Leukopenia 12 0 0 0 0 
TCP & Anaemia & Leukopenia 152 4 (2.63%) 0 0 0 







Table 6. SVR rates according to different status of TCP, anaemia, and leukopenia, and different 
management of AVT. 









TCP      
Non-TCP 68.7 (65.0-72.1) 70.3 (64.4-75.8) 20.6 (15.9-26.0) 30.8 (23.1-39.4) 55.8 (63.1-58.4) 
Acquired at baseline 53.8 (47.7-59.8) 47.7 (41.8-53.7) 6.7 (3.3-12.0) 18.1 (13.0-24.3) 36.5 (33.4-39.7) 
Acquired during AVT 61.4 (58.8-64.0) 66.7 (63.0-70.3) 27.9 (23.3-32.9) 34.3 (28.7-40.3) 55.5 (53.6-57.4) 
Anaemia      
Non-anaemia 63.8 (61.6-66.0) 62.4 (58.7-66.0) 20.8 (17.7-24.2) 23.5 (19.3-28.0) 51.7 (50.0-53.3) 
Acquired at baseline 35.7 (12.8-64.9) 16.7 (3.6-41.4) 0.0* (--) 25.0 (3.2-65.1) 21.7 (9.8-33.7) 
Acquired during AVT 58.3 (53.5-63.0) 65.5 (61.1-69.8) 24.6 (17.2-33.2) 37.7 (31.1-44.8) 54.4 (51.6-57.2) 
Leukopenia      
Non-leukopenia 63.0 (60.9-65.0) 63.4 (60.4-66.2) 21.7 (18.8-24.8) 26.8 (23.1-30.7) 52.1 (50.7-53.6) 
Acquired at baseline 33.3 (0.8-90.6) 16.7 (0.4-64.1) --# 50.0 (1.3-98.7) 27.3 (1.0-53.6) 
Acquired during AVT 56.0 (45.2-66.4) 61.5 (51-71.2) 5.0 (0.1-24.9) 44.9 (30.7-59.8) 52.0 (45.8-58.1) 
*There were 6 patients who had baseline anaemia and underwent dose cessation, but none of them achieved 















Age at initiation of AVT 0.97 (0.96 – 0.98) < 0.001 0.98 (0.98 – 0.99) < 0.001 
Gender 
    Male vs Female 
 








    White vs Non-white 
 








    Genotype 3 vs 1 
    Others vs 1 
 
2.56 (2.27 – 2.89) 





2.45 (2.16 – 2.78) 





    Yes vs No 
 








    Yes vs No 
 








    Experienced vs Naïve  
 








    Abnormal vs Normal 
 








    Abnormal vs Normal 
 





    Abnormal vs Normal 
 








    Abnormal vs Normal 
 




0.76 (0.54 – 1.07) 
 
0.114 
Baseline TCP 0.46 (0.4 – 0.53) < 0.001 0.67 (0.56 – 0.81) < 0.001 
Baseline anaemia 0.25 (0.13 – 0.51) < 0.001 0.43 (0.2 – 0.92) 0.03 
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Baseline leukopenia 0.34 (0.09 – 1.3) 0.115  
OR: odds ratio. 
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